Pfizer Inc.

Recent Events

News & Analysis

mike huckman and pfizer inc. - All News and Analysis

• Biopharma, Especially Merck, Having a Good Week

  Seeking Alpha - 2009-03-13

  Mike Huckman submits: Shares of Dow component Merck MRK are getting a nice little shot in the arm this morning on an upgrade by Dr. Tim Anderson at Sanford C. Bernstein. He's putting an "Outperform" or "Buy" rating on MRK and raising his target price three bucks to $30....

  Tags: Biotech, Mike Huckman, Merck & Co. Inc., Pfizer Inc.

• Will Pfizer's Pancreatic Cancer Breakthrough Help the Stock?

  Seeking Alpha - 2009-03-13

  Mike Huckman submits: When a press release crosses the wires or pops into the inbox from a Dow component announcing positive late-stage test results on a cancer drug, you rush to get the headlines on the air as quickly as possible. That's the nature of the TV-news biz beast....

  Tags: Healthcare, Mike Huckman, Pfizer Inc.

• Genentech Overtakes Pfizer - Briefly

  Seeking Alpha - 2009-02-28

  Mike Huckman submits: As I was Googling around looking for articles to use as homework for the upcoming Genentech meeting, I stumbled across this nugget on Matthew Herper's "Science Business" blog over at "Forbes." When I wasn't looking, the market value of biotech giant Genentech DNA surpassed the market...

  Tags: Biotech, Mike Huckman, Genentech Inc., Pfizer Inc.

• Pfizer: The F Is for February Failures

  Seeking Alpha - 2009-02-24

  Mike Huckman submits: Zero for three - that's Pfizer's PFE unfortunate drug development record this month. This morning the world's biggest pharmaceutical firm announced that it's scrapping two more drugs that were in late-stage studies. That's on top of the experimental pancreatic cancer treatment PFE gave up on...

  Tags: Healthcare, Mike Huckman, Pfizer Inc.

• Pfizer / Wyeth: The Dust's Still Settling

  Seeking Alpha - 2009-02-12

  Mike Huckman submits: I thought the dust had pretty much settled on the Pfizer-Wyeth story. Then this morning two analysts coincidentally put out research notes on it. One of them is upgrading Pfizer PFE to the equivalent of a "Buy" rating. But the other is lowering his target price...

  Tags: Healthcare, Mike Huckman, Pfizer Inc., Wyeth

• Pfizer Scraps Pancreatic Cancer Drug

  Seeking Alpha - 2009-02-03

  Mike Huckman submits: So, what do you do at the end of a week where your company's stock was the worst performer in the Dow and you've got some bad news that could make the shares go down even more? You employ one of the oldest PR tricks in...

  Tags: Healthcare, Mike Huckman, Pfizer Inc.

• Is Pfizer Now Interested in a Merger?

  Seeking Alpha - 2009-01-05

  Mike Huckman submits: AP The "Financial Times" apparently got a one-on-one interview with Pfizer PFE Chairman and CEO Jeff Kindler and is playing up what he said with the headline, "Pfizer eyes merger deal with large rival." That conclusion is based on this quote: "We are open to opportunities and...

  Tags: Healthcare, Mike Huckman, Pfizer Inc.

• Short Interests in Pfizer and Dendreon Decline - Is Bearish Sentiment Dissipating?

  Seeking Alpha - 2008-12-03

  Mike Huckman submits: I know that simply pointing this out will draw the ire of certain Pfizer PFE investors who happen to read my blog, but the fact is that PFE is the only major pharmaceutical company whose short interest is big enough to crack the Barron's Top-40. PFE...

  Tags: Biotech, Healthcare, Mike Huckman, Dendreon Corp., Pfizer Inc.

• Surprise, Pfizer Study Says Lipitor Beats Generic Zocor

  Seeking Alpha - 2008-12-03

  Mike Huckman submits: CNBC.comTuesday afternoon the "Journal of the American Medical Association" (JAMA) published a study showing that cheaper, generic heart drugs work just as well as more expensive, brand-name heart drugs. by Mike Huckman

  Tags: Healthcare, Mike Huckman, Merck & Co. Inc., Pfizer Inc.